Abstract Details

Title The role of serum neurofilament light chain in an adult cohort of patients with acquired demyelinating syndromes of the central nervous system

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-006

Objective

To investigate the role of serum Neurofilament light chain (sNfL) levels in adult patients with acquired demyelinating syndromes (ADS) of the central nervous system.

Background

The concentration of sNfL has been found to increase in serum of patients with CNS diseases, associated with axonal injury or degeneration.

Design/Methods A total of 347 patients were evaluated, a propensity score matching was performed to select patients with homogeneous baseline characteristics. It retained n=17 multiple sclerosis(MS), n=15 Myelin Oligodendrocytes Glycoprotein Antibody associated Disorder(MOGAD), n=16 Neuromyelitis Optica Spectrum Disorders(NMOSD) patients and n=24 Healthy Controls(HCs). Demographic, clinical features and samples were collected at disease onset(T0). SNfL was measured using ultrasensitive single-molecule array assays (SIMOA). MOG-IgG and AQP4-IgG were analyzed by an in-house cell-based assay. In a subgroup of NMOSD and MOGAD patients, the autoantibodies and sNfL were longitudinally evaluated after the DMD initiation(T1).

Results MOGAD patients showed a significant lower sNFL levels compared to MS(median 16,47pg/mL range 5,10-71,78 vs 7,34 range 2,43-115,43; p=0.01) and NMOSD adult patients(median 16,46pg/mL range 4,2-196,47; p=0.02). All groups had an increased sNFL value compared to HCs(median 5,64pg/mL range 2,47-8,84; p<0.0001). A positive significant correlation was found between sNfL and EDSS scores in MOGAD (r=0.636; p=0.005), NMO-AQP4 (r=0.908; p<0.0001) and MS patients (r=0.534; p = 0.014). No correlation was found between MOG-IgG titers and sNfL levels (p=0.294). In NMOSD (p=0,04) and MOGAD (p=0,008) patients presented a decrease of the antibody titer at T1. In 2/6 NMOSD and 4/10 MOGAD patients, sNfL resulted increased at T1.

Conclusions

To our knowledge, this is the first study where sNfL levels were compared in a matched cohort of ADS patients and at the same disease stage. Our results confirm the value of sNfL as a clinically meaningful blood biomarker of disease severity and activity in all groups and that the antibody titer is not related to the axonal damage.

Authors/Disclosures
PRESENTER	No disclosure on file
Pietro Iaffaldano	Pietro Iaffaldano has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Tommaso Guerra	Tommaso Guerra has nothing to disclose.
Alessia Manni	Alessia Manni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Alessia Manni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi genzime. Alessia Manni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Alessia Manni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Damiano Paolicelli	Damiano Paolicelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. Damiano Paolicelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
Marta Simone	Marta Simone, 11772 has nothing to disclose.
	No disclosure on file
Maria Trojano (Policlinico - Bari)	Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi_Genzyme. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Maria Trojano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen.

��ɫ��

��ɫ��